Tom Robinson, vice president of global access at JDRF, talks about the predictive modeling exercise used to develop and refine the Type 1 Diabetes (T1D) Index.
Collaborating with experts from different groups, countries, and academic disciplines helped formulate refinements to the Type 1 Diabetes (T1D) Index, said Tom Robinson, vice president of global access at JDRF.
Transcript
What research went into developing the T1D Index, especially to create more specific estimates?
From the start, we knew that we had to deal with the challenge of scarce data. We don't have registries in every country, we're not gonna get them anytime soon, although that's what we need to get to eventually. So we decided to engage in a predictive modeling exercise and we got some really good data scientists to help us with that. What they steered us towards is an iterative and collaborative approach. So, iterative in the sense that we built the first version of the model in a week, and the guys who did it, Gabriel Gregory, he did not sleep. But at the end of the week, we had our first estimate and it was not terrible, it was actually a pretty decent start. But then we said, "okay, well, how can we improve it?" And that's where the collaborative came in.
We started bringing in experts from different groups, different countries, different academic disciplines, and they'd come in and they'd challenge us in 1 of 2 ways. One would be to say, "I don't like your methods, I don't think they're valid, or you should try different approach." Or they'd say, "hey, the numbers don't seem right in this respect. There's too many old people, or there's not enough people in this setting, or you're overestimating how many people might be in Central Africa."
By holding that model up to reality, we could see, oh actually, you know what we need to do? We have a problem with regionality in Canada, or our mortality model is too consistent across all ages—we need to make sure it flexes by age more—so we started making these methodological refinements. That was the process we went through and we were probably in that phase for about 18 months, 12 to 18 months before we started to see the numbers become very consistent. Then we spent another 12 months continuing to iterate and seeing that those changes didn't move the numbers very much. It was at that point we said, okay, this is pretty solid now, it's time to start thinking about publishing.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More